GlassScriptPhysician profile
James J Kennedy
NPI 1780698985
$14,713.20
in general payments reported to CMS, 2019-2025
32 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,565 · 2020: $1,891 · 2021: $2,299 · 2022: $1,809 · 2023: $2,042 · 2024: $1,904 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,149.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,816.43 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $1,303.90 | 2019-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,302.70 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $1,276.97 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $1,076.03 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $934.39 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $831.80 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $811.18 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $741.44 | 2020-2025 | Caplyta |
| Alkermes, INC. | $679.77 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Bausch Health US, LLC | $650.80 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $510.98 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $470.30 | 2023-2025 | Auvelity, Sunosi |
| Avanir Pharmaceuticals, INC. | $358.43 | 2019-2020 | |
| Tris Pharma INC | $328.29 | 2022-2025 | Dyanavel Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $312.79 | 2019-2020 | |
| Corium, LLC | $191.14 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $168.96 | 2022-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $149.99 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Almatica Pharma LLC | $120.80 | 2022-2023 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $116.83 | 2019-2020 | |
| Eisai INC. | $113.09 | 2020-2021 | |
| Adlon Therapeutics L.P. | $101.37 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $81.57 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $77.36 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $47.14 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $41.03 | 2022-2023 | Belsomra |
| Shire North American Group INC | $28.49 | 2019 | |
| Noven Therapeutics, LLC | $20.00 | 2024 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $17.30 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $16.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.